NAMUR, Belgium, May 18,
2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT:
VNRX) today announced the publication of a research paper
entitled "Circulating
nucleosomes as new blood-based biomarkers for detection of
colorectal cancer". The study was published in Clinical
Epigenetics in collaboration with the CHU UCL Namur, Site de
Mont Godinne, Belgium.
Volition's Chief Executive Officer, Cameron Reynolds, commented, "I am delighted
that this paper reporting one of our earlier pilot studies has been
accepted for peer review publication. To detect colorectal cancer
and pre-cancerous polyps with such high accuracy is extremely
encouraging, particularly the high early-stage detection. We are
focused on using these exciting results to develop our frontline
product. Our product development process involves large trials of
thousands of patients and extensive assay development work at our
new purpose-built facility in Belgium."
The lead author of the paper, Professor Jean-François Rahier, is
a gastroenterologist and a recognized member of the Belgian
research group on inflammatory diseases BIRD (Belgian IBD Research
group) and the European group ECCO (European Crohn and Colitis
Organization). Professor Rahier commented, "The development of
better methods for the early detection of colorectal cancer is
critical for the improvement of patients' survival rates. We have
found that a Nu.Q™ panel test detects colorectal cancer and
pre-cancer with high accuracy, indicating it may prove to be useful
as a routine clinical colorectal cancer blood test."
Our four Nu.Q™ assays demonstrated Colorectal Cancer (CRC)
detection accuracy of 74% sensitivity at 90% specificity and
detected all stages of the cancer, including 75% of early stage I
cancers. The study also showed that by using an age adjusted
scoring system the accuracy of CRC detection increased to 91% of
cancers at 90% specificity. The study consisted of 58 patients over
50 years of age classified into three groups based on their
colonoscopy reports: (i) patients with CRC (n = 23), (ii) patients
with polyps (n = 16), and (iii) healthy controls with no endoscopic
lesions (n = 19).
The results in early stage cancers showed to be particularly
positive in comparison to the current, most commonly used blood
test for colorectal cancer, Carcinoembryonic Antigen (CEA). In this
study, in comparison to the Nu.Q™ results, the CEA results gave a
detection rate of 35% of cancers overall at 90% specificity;
however, critically, CEA detected no stage I cancers. Not only did
the study show very good early stage detection with
Nu.Q™ assays, it also demonstrated high pre-cancer polyp
detection, with a different Nu.Q™ panel of four assays detecting
62% of polyps at 90% specificity. These are both extremely
encouraging outcomes of the study.
A copy of the full paper can be found on our website at
http://volitionrx.com/downloads
About Volition
Volition is a multi-national life sciences company developing
simple, easy to use blood-based cancer tests to accurately diagnose
a range of cancers. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid --
an indication that disease is present.
As cancer screening programs become more and more widespread,
our products aim to help to diagnose a range of cancers quickly,
simply, accurately and cost effectively. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life.
Volition's research and development activities are currently
centered in Belgium, with
additional offices in London,
New York, Texas and Singapore, as the company focuses on bringing
its diagnostic products to market first in Europe, then in the U.S. and ultimately,
worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition
L.day@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
S.powell@volitionrx.com
+1 (646) 650
1351
|
Tirth Patel,
Edison Advisors
tpatel@edisongroup.com
+1 (646) 653
7035
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077
5711
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to the effectiveness of Volition's bodily-fluid-based diagnostic
tests as well as Volition's ability to develop and successfully
commercialize such test platforms for early detection of cancer.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties. For instance, if Volition fails to develop and
commercialize diagnostic products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products in the clinical
IVD market; a failure by the marketplace to accept the products in
Volition's development pipeline or any other diagnostic products
Volition might develop; Volition will face fierce competition and
Volition's intended products may become obsolete due to the highly
competitive nature of the diagnostics market and its rapid
technological change; and other risks identified in Volition's most
recent Annual Report on Form 10-K and Quarterly Reports on Form
10-Q, as well as other documents that Volition files with the
Securities and Exchange Commission. These statements are based on
current expectations, estimates and projections about Volition's
business based, in part, on assumptions made by management. These
statements are not guarantees of future performance and involve
risks, uncertainties and assumptions that are difficult to predict.
Forward-looking statements are made as of the date of this release,
and, except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics®, NuQ®, Nu.Q™ and HyperGenomics® and
their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks,
service marks and trade names referred to in this press release are
the property of their respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/a-new-publication-reports-that-91-of-colorectal-cancers-were-detected-at-90-specificity-in-a-completed-prospective-trial-using-volitions-nuqtm-assays-300459980.html
SOURCE VolitionRx Ltd.